Drug
Imlunestrant
Imlunestrant: highest development phase Phase 2, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Imlunestrant NCT07287098 | Phase 2 | Breast Neoplasms |
| Imlunestrant (Test) NCT07918859 | Phase 1 |
Latest
No recent events.
Follow Imlunestrant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.